The Cooper Companies, Inc. (COO) Earnings Call Transcripts

The Cooper Companies, Inc.'s Latest Earnings Call - Q3 FY2026

In Q3 2026, The Cooper Companies reported consolidated revenue of $1.066 billion, reflecting a 1% increase year-over-year, while non-GAAP EPS rose 4% to $1.15, exceeding expectations for the 11th consecutive quarter. The company faced challenges in CooperVision due to proactive U.S. channel inventory reductions, resulting in flat revenue of $717 million, but management indicated healthy underlying demand with mid-single-digit consumption growth. Guidance for Q4 revenue is set between $1.057 billion and $1.080 billion, with CooperVision expected to decline 2% to flat organically, while CooperSurgical is projected to grow 4% to 6%.

Reported metrics

Guidance from management

For Q4, management expects consolidated revenue of $1.057 billion to $1.080 billion and non-GAAP EPS of $1.05 to $1.09. Guidance reflects continued challenges in CooperVision due to inventory management but positive growth expectations for CooperSurgical.

What management said

Yes, Jon, it's all destock. So the consumption in the U.S. market here has been running pretty steady all year in the mid-single digits. It was -- it did in Q3, and it did in the first month of this quarter. So I would expect consumption to remain as is. Meaning the entire reason for the reduction in the revenue guidance for CooperVision was tied to just channel inventory. That's it.

Yes. A couple of things on that. I mean, some of the moves that we're making that you see here in the U.S. with respect to the channel inventory are one that's impacting us. Another one that's impacting us has been for a little bit and will to end this year. is some of the portfolio rationalization we're doing with our legacy hydrogels. Our legacy hydrogels were down double digit across the board as we continue to ki...

What analysts pressed on

Analysts expressed concerns regarding the impact of inventory destocking on future revenue growth, particularly in CooperVision. There were also questions about the sustainability of growth in the Asia Pacific region, especially in light of recent performance in China and the competitive landscape.

Main topics on the call

• Inventory Management Challenges — CooperVision's proactive reduction of U.S. channel inventory impacted revenue, with management stating, 'the entire reason for the reduction in the revenue guidance for CooperVision was tied to just channel inventory.' T...
• Strong Free Cash Flow Generation — The company achieved record free cash flow of $273 million, the highest in its history, driven by strong operational performance and improved working capital trends. This reinforces confidence in their goal of generating...
• Strategic Review Conclusion — The Board concluded the strategic review, deciding against selling CooperSurgical, citing a 'temporary disconnect between CooperSurgical's intrinsic value and the offers received.' Management emphasized a focus on organi...
• Future Growth Initiatives — Management outlined plans to enhance CooperVision's revenue performance through expanded sales coverage and marketing initiatives, stating, 'we're investing in expanded sales coverage, increased customer marketing progra...

Read the full The Cooper Companies, Inc. transcript (Q3 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 53 The Cooper Companies, Inc. earnings call transcripts on record, spanning January 15, 2020 to September 9, 2026. Based on this history, The Cooper Companies, Inc. reports quarterly. The most recent call on file is dated September 9, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

COO

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

53

First call

January 15, 2020

Most recent

September 9, 2026

Reporting cadence

quarterly